Pfizer/IVGTT/Ziprasidone/Olanzapine
Schizophrenia, Type 2 Diabetes Mellitus
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia, BMI, T2DM
Eligibility Criteria
Inclusion Criteria: Patients: meets DSM-IV criteria for schizophrenia, any type, or schizoaffective disorder; aged 18 to 60 years; able to give informed consent; no medication changes for 2 weeks prior to and during the period of study; Patients: currently taking an antipsychotic. Exclusion Criteria: Controls: Axis I psychiatric disorder criteria met except for substance use disorders as below; meets DSM-IV criteria for the diagnoses of substance abuse or dependence within the past six months; involuntary legal status (as per Missouri law); the presence of any serious medical disorder that may (as confirmed by peer-reviewed literature) confound the assessment of symptoms, relevant biologic measures or diagnosis; the following conditions are currently identified: insulin- or non-insulin-dependent diabetes mellitus; any intra-abdominal or intrathoracic surgery or limb amputation within the prior 6 months; any diagnosed cardiac condition causing documented hemodynamic compromise; any diagnosed respiratory condition causing documented or clinically recognized hypoxia; pregnancy or high dose estrogens, fever, narcotic therapy, acute sedative hypnotic withdrawal, corticosteroid or spironolactone therapy, dehydration, epilepsy, endocrine disease, high-dose benzodiazepine therapy (> 25 mg/day of diazepam), or any medical condition known to interfere with glucose utilization; meets DSM-IV criteria for Mental Retardation (mild or worse).
Sites / Locations
- Washington University School of Medicine, Psychiatry Dept.